Bookmark Kaumudi Online  Bookmark this site  Editor@Kaumudi  |  Marketing  Print Advt rates  |  Calendar 2018        Go!    
 
 
September 19, Wednesday 2018 8:16 PM       

       HEADLINES: Raw chicken cost dips but hoteliers' price doesn't                                              Bishop to be questioned at Thripunithura                                              Such kinky ‘cops’ are shame to Kerala Police (video)                                              FB freak traps gullible girls using his morphed pics, lies                                              Nun’s sister’s condition worsens; hospitalised                                              Cabinet clears ordinance to make triple talaq penal offence: Law Minister                                              Forces within JNU 'waging war against India', says Sitharaman                                              US-China trade war could last for 20 years: Jack Ma                                              Didn't expect Arjuna this year: Hima Das                                              Kaumudi Facebook
       SCI&TECH Next Article: Here is how you can travel smart using these apps!  
       A new ray of hope for breast cancer patients!
 
         Posted on :23:35:15 Mar 22, 2018
   
A A
       Last edited on:23:35:15 Mar 22, 2018
         Tags: Three-part molecule, Breast cancer patients
 

WASHINGTON DC: A new ray of hope has been found for breast cancer patients.

A newly designed three-part molecule could be the one answer patients with a certain form of breast cancer are looking for, according to a study conducted by the Medical College of Georgia at Augusta University.

This chimera, created by a team at the Georgia Cancer Center, has the ability to simultaneously decrease the expression of three growth factors that are over-expressed in some cancers.

The growth factors are human epidermal growth factor receptor 2 (HER2), human epidermal growth factor receptor 3 (HER3), and epidermal growth factor receptor (EGFR).

The new chimera interferes with HER2 and HER3 signaling and ultimately leads to cancer cell death.

"When HER2 is expressed in a cell, you'll usually find high expression of HER3, too," said researcher Hongyan Liu.

Extensive studies have found that 20-30 percent of breast cancers are characterized by over-expression of HER2, which makes the cancer cells grow and divide faster, leading to a cancer that's more aggressive and more likely to be resistant to the standard of care.

Patients with this type of breast cancer tend to have a poorer prognosis. "As a bioengineer, I am developing the materials for cancer-targeted treatment," Liu said.

"I have experience building multifunctional chimeras to target different types of genes associated with cancer cells."

Liu and her team created their molecule to target HER family receptors EGFR, HER2, and HER3 all at once, since it is well-known that another HER family member can compensate for one that is blocked by a drug having a single target.

Each component of this tripartite molecule has potent anti-tumor activity. The molecule was designed such that the EGFR-targeting component is sandwiched between the HER2- and HER3-targeting components in what is known as a HER2 aptamer-EGFR siRNA-HER3 aptamer chimera.

This construction enables the EGFR component to reach its target within HER2- and HER3-expressing cells. Compared to individual components, the chimera is large enough to avoid renal depletion, resulting in a prolonged circulation time and increased efficiency.

The newly crafted molecule is non-toxic, simple to produce, and cost-effective compared to the production of alternate treatment strategies, such as antibodies and small molecule inhibitors.

Liu's ongoing studies are testing the ability of the three-in-one chimera to treat breast cancers that are resistant to Herceptin, a drug that targets HER2.

This work is being done in collaboration with Dr. Hasan Korkaya who has developed drug-resistant cell lines, and with breast cancer clinicians.

"We need to prove that this molecule will work on Herceptin-resistant breast cancer patients," Liu said.

Since other cancers, such as lung and head and neck, proliferate due to HER family over-expression, Liu anticipates that the chimera's utility will not be limited to breast cancers alone.

The findings from this study are published in the publication Molecular Therapy: Nucleic Acids.

A A
       SCI&TECH
Next Article: Here is how you can travel smart using these apps!
 
 
SCI&TECH HEADLINES
Pluto should be reclassified as a planet, reveals study  
Shared responsibility essential for conserving migratory species  
Microsoft releases Speech Corpus for three Indian languages  
Facebook likely to run on 100% renewable energy by 2020  
Can brain suppress the act of revenge?  
Kerala techies launch portal to facilitate relief measures  
Here's what you may not know about H2O  
Alexa will tell you when it has done its homework  
Students recreate horrific atomic bombings of Hiroshima using VR technology  
Study discovers compounds that can reverse cell ageing  
Online interactive courses on AI in trading, first time on internet  
Apple to fix devices damaged by Japan's floods for free  
IT industry should focus on developing new technologies  
Skype adds read receipts to chats  
Mobile app for replacement of transformers in Raj  
Kashmiri students make solar boat for Dal Lake  
NASA prepares to fly probe into Sun's scorching atmosphere  
Yoga helps against non-communicable diseases: WHO  
Spironolactone can help prevent acne: Study  
Older Amazonian forests help regulate global climate  
Goal conflict linked to depressive symptoms  
A new world: Top 10 new species for 2018  
Beat the risk of frailty with healthy heart  
Twitter to hide trolls that hurl abuse: Twitter CEO  
Fortnite is finally coming to Android  
 
Do you think forced salary challenge is acceptable in the current situation?
yes
 
not
 
don't know
 
 
 
Home Kerala India World Business Sports Sci&Tech Education Automobile CityNews Movies Environment Letters 
© Copyright keralakaumudi Online 2011  |  Reproduction in whole or in part without written permission is prohibited.
Head Office Address: Kaumudi Buildings, Pettah P.O, Trivandrum - 695024, India.
Online queries talk to Deepu Sasidharan, + 91 98472 38959 or Email deepu[at]kaumudi.com
Customer Service -Advertisement Disclaimer Statement   |  Copyright Policy